<!DOCTYPE html><html lang="en"> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>Module 3: Respiratory & Allergic Emergencies</title> <style> /* Main Styles from Previous Document - EXACT MATCH */ body { font-family: 'Calibri', 'Segoe UI', sans-serif; line-height: 1.5; color: #2c3e50; margin: 2cm; background-color: #ffffff; counter-reset: chapter section figure table; }
    h1 {
        font-size: 28pt;
        font-weight: bold;
        color: #1a5276;
        text-align: center;
        border-bottom: 3px double #3498db;
        padding-bottom: 10px;
        margin-bottom: 30px;
    }
    
    h2 {
        font-size: 18pt;
        font-weight: bold;
        color: #ffffff;
        background-color: #2980b9;
        padding: 10px 15px;
        border-radius: 5px;
        margin-top: 30px;
        page-break-after: avoid;
    }
    
    h3 {
        font-size: 14pt;
        font-weight: bold;
        color: #154360;
        margin-top: 20px;
        margin-bottom: 10px;
        page-break-after: avoid;
    }
    
    h4 {
        font-size: 12.5pt;
        font-weight: bold;
        color: #21618c;
        margin-top: 15px;
        margin-bottom: 8px;
    }
    
    .module-title {
        font-size: 20pt;
        font-weight: bold;
        color: #21618c;
        margin-top: 40px;
        border-left: 6px solid #3498db;
        padding-left: 15px;
    }
    
    .chapter-number {
        background-color: #3498db;
        color: white;
        padding: 5px 12px;
        border-radius: 50%;
        display: inline-block;
        margin-right: 10px;
        font-weight: bold;
    }
    
    /* Lists */
    ul, ol {
        padding-left: 1.5em;
        margin-bottom: 1em;
    }
    
    li {
        margin-bottom: 8px;
        font-size: 11.5pt;
    }
    
    .sub-list {
        list-style-type: lower-alpha;
        padding-left: 2.5em;
    }
    
    .drug-list {
        columns: 2;
        column-gap: 50px;
        margin-top: 15px;
    }
    
    .drug-list li {
        break-inside: avoid;
    }
    
    /* Special Boxes - EXACT MATCH */
    .study-format {
        background-color: #e8f4fc;
        border: 1px solid #aed6f1;
        border-left: 6px solid #2e86c1;
        padding: 20px;
        margin-top: 30px;
        page-break-inside: avoid;
    }
    
    .clinical-pearl {
        background-color: #fff3cd;
        border: 1px solid #ffeaa7;
        border-left: 6px solid #fdcb6e;
        padding: 15px;
        margin: 15px 0;
        border-radius: 0 5px 5px 0;
    }
    
    .warning-box {
        background-color: #f8d7da;
        border: 1px solid #f5c6cb;
        border-left: 6px solid #e74c3c;
        padding: 15px;
        margin: 15px 0;
        border-radius: 0 5px 5px 0;
    }
    
    .definition-box {
        background-color: #d1ecf1;
        border: 1px solid #bee5eb;
        border-left: 6px solid #17a2b8;
        padding: 15px;
        margin: 15px 0;
        border-radius: 0 5px 5px 0;
    }
    
    /* Tables - EXACT MATCH */
    .comparison-table {
        width: 100%;
        border-collapse: collapse;
        margin: 20px 0;
        font-size: 11pt;
    }
    
    .comparison-table th {
        background-color: #2980b9;
        color: white;
        padding: 10px;
        text-align: left;
        border: 1px solid #1a5276;
    }
    
    .comparison-table td {
        padding: 10px;
        border: 1px solid #ddd;
        vertical-align: top;
    }
    
    .comparison-table tr:nth-child(even) {
        background-color: #f8f9fa;
    }
    
    /* Figures and Captions - EXACT MATCH */
    .figure {
        text-align: center;
        margin: 20px 0;
        page-break-inside: avoid;
    }
    
    .figure img {
        max-width: 100%;
        height: auto;
    }
    
    .caption {
        font-style: italic;
        font-size: 10.5pt;
        color: #666;
        margin-top: 5px;
        text-align: center;
    }
    
    /* Page Layout - EXACT MATCH */
    .page-break {
        page-break-before: always;
    }
    
    .footer-note {
        font-size: 9pt;
        color: #7f8c8d;
        text-align: center;
        margin-top: 30px;
        border-top: 1px solid #ecf0f1;
        padding-top: 10px;
    }
    
    /* Drug Template - EXACT MATCH */
    .drug-template {
        background-color: #f9f9f9;
        border: 1px solid #ddd;
        padding: 20px;
        margin: 25px 0;
        border-radius: 5px;
        page-break-inside: avoid;
    }
    
    .drug-template h4 {
        color: #2c3e50;
        border-bottom: 2px solid #3498db;
        padding-bottom: 5px;
        margin-top: 0;
    }
    
    .template-section {
        margin-bottom: 15px;
    }
    
    .template-label {
        font-weight: bold;
        color: #2980b9;
        display: inline-block;
        width: 180px;
    }
    
    /* Emoji Styling - EXACT MATCH */
    .emoji {
        font-size: 1.2em;
    }
    
    /* Print Specific - EXACT MATCH */
    @media print {
        body {
            margin: 1.5cm;
            font-size: 11pt;
        }
        
        .page-break {
            page-break-before: always;
        }
        
        .no-print {
            display: none;
        }
        
        a {
            color: black;
            text-decoration: none;
        }
    }
    
    /* Learning Objectives - EXACT MATCH */
    .learning-objectives {
        background-color: #e8f6f3;
        border: 1px solid #a2d9ce;
        padding: 15px;
        margin: 20px 0;
        border-radius: 5px;
    }
    
    .objective-list {
        list-style-type: none;
        padding-left: 0;
    }
    
    .objective-list li:before {
        content: "‚úì ";
        color: #27ae60;
        font-weight: bold;
        margin-right: 10px;
    }
    
    /* Additional Styles for Module 3 */
    .asthma-box {
        background-color: #e8f4fc;
        border: 2px solid #5dade2;
        padding: 20px;
        margin: 20px 0;
        border-radius: 8px;
    }
    
    .anaphylaxis-alert {
        background-color: #fdebd0;
        border: 2px solid #f39c12;
        color: #d35400;
        padding: 15px;
        margin: 20px 0;
        font-weight: bold;
        border-radius: 5px;
        text-align: center;
    }
    
    .severity-box {
        background-color: #f2f4f4;
        border: 1px solid #bdc3c7;
        padding: 15px;
        margin: 15px 0;
        border-left: 4px solid #7f8c8d;
    }
    
    .breathing-algorithm {
        background-color: #eafaf1;
        border: 2px solid #58d68d;
        padding: 20px;
        margin: 20px 0;
        border-radius: 8px;
        font-family: 'Courier New', monospace;
        font-size: 11pt;
    }
    
    .peak-flow-card {
        background-color: #fef9e7;
        border: 1px solid #f7dc6f;
        border-left: 4px solid #f1c40f;
        padding: 15px;
        margin: 15px 0;
        border-radius: 5px;
    }
    
    /* Module 3 Specific Colors */
    .respiratory-blue {
        color: #2980b9;
        font-weight: bold;
    }
    
    .allergy-red {
        color: #e74c3c;
        font-weight: bold;
    }
    
    .steroid-green {
        color: #27ae60;
        font-weight: bold;
    }
</style>
</head> <body>
<div class="module-title">
    <span class="emoji">üü¶</span> MODULE 3: RESPIRATORY & ALLERGIC EMERGENCIES
    <div style="font-size: 12pt; font-weight: normal; font-style: italic; color: #7f8c8d;">
        (Breathing Emergencies & Anaphylaxis)
    </div>
</div>

<div class="learning-objectives">
    <h3 style="color: #148f77; margin-top: 0;">üìñ Learning Objectives</h3>
    <ul class="objective-list">
        <li>Master the management of severe asthma exacerbations and status asthmaticus</li>
        <li>Understand the pathophysiology and treatment of anaphylaxis</li>
        <li>Learn the role of corticosteroids in respiratory emergencies</li>
        <li>Differentiate between beta-agonists and anticholinergics in asthma/COPD</li>
        <li>Recognize when to escalate from inhaled to systemic therapy</li>
        <li>Manage acute angioedema and upper airway obstruction</li>
        <li>Understand drug interactions in respiratory medications</li>
        <li>Apply knowledge to clinical scenarios and exam questions</li>
    </ul>
</div>

<!-- INTRODUCTION -->
<h2><span class="chapter-number">0</span> Introduction: The Breath of Life</h2>

<div class="warning-box">
    <strong>‚ö†Ô∏è TIME IS OXYGEN:</strong> For every minute of hypoxia, brain cells die. Respiratory emergencies require immediate recognition and intervention. Never delay treatment while waiting for investigations.
</div>

<div class="clinical-pearl">
    <strong>üß† Core Concept:</strong> Respiratory emergencies involve two main pathologies:<br>
    1. <strong class="respiratory-blue">Airway Obstruction</strong> (asthma, anaphylaxis, foreign body)<br>
    2. <strong class="respiratory-blue">Gas Exchange Impairment</strong> (pneumonia, ARDS, pulmonary edema)<br>
    This module focuses on obstructive emergencies and their pharmacological management.
</div>

<!-- CHAPTER 1: SEVERE ASTHMA MANAGEMENT -->
<h2><span class="chapter-number">1</span> Severe Asthma & Status Asthmaticus</h2>

<div class="definition-box">
    <strong>Status Asthmaticus:</strong> A severe, life-threatening asthma exacerbation that fails to respond to conventional therapy with beta-agonists and systemic corticosteroids. Characterized by progressive respiratory distress leading to respiratory failure.
</div>

<h3>1.1 Asthma Severity Assessment</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 20%;">Severity</th>
            <th>Clinical Features</th>
            <th>Peak Flow</th>
            <th>Blood Gases</th>
            <th>Action</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Mild</strong></td>
            <td>Speaks in sentences, mild wheeze, RR increased</td>
            <td>‚â•70% predicted</td>
            <td>Normal or mild resp alkalosis</td>
            <td>Nebulized beta-agonist, oral steroids</td>
        </tr>
        <tr>
            <td><strong>Moderate</strong></td>
            <td>Speaks in phrases, audible wheeze, accessory muscles</td>
            <td>40-69% predicted</td>
            <td>Normal PaCO‚ÇÇ, PaO‚ÇÇ may be low</td>
            <td>Frequent nebs, IV steroids, consider IV magnesium</td>
        </tr>
        <tr>
            <td><strong>Severe</strong></td>
            <td>Speaks in words, silent chest, exhaustion, cyanosis</td>
            <td><40% predicted</td>
            <td>PaCO‚ÇÇ normal or rising (ominous sign)</td>
            <td>Continuous nebs, IV magnesium, IV beta-agonists, prepare for intubation</td>
        </tr>
        <tr>
            <td><strong>Life-threatening</strong></td>
            <td>Confusion, drowsiness, bradycardia, silent chest</td>
            <td>Unable to perform</td>
            <td>Hypercapnia, acidosis, hypoxemia</td>
            <td>IV therapy, ICU admission, intubation imminent</td>
        </tr>
    </tbody>
</table>

<h3>1.2 Asthma Management Algorithm</h3>

<div class="breathing-algorithm">
    <strong>STEP 1: ASSESS & OXYGENATE</strong><br>
    ‚Ä¢ High-flow oxygen (target SpO‚ÇÇ 94-98%)<br>
    ‚Ä¢ Assess severity: Speech, work of breathing, auscultation<br>
    ‚Ä¢ Peak flow if possible<br>
    ‚Ä¢ ABG if severe<br>
    <br>
    <strong>STEP 2: BRONCHODILATORS</strong><br>
    ‚Ä¢ Salbutamol 5 mg nebulized + Ipratropium 0.5 mg (back-to-back)<br>
    ‚Ä¢ Repeat every 20 minutes √ó 3 if severe<br>
    ‚Ä¢ Consider continuous nebulization if life-threatening<br>
    <br>
    <strong>STEP 3: STEROIDS</strong><br>
    ‚Ä¢ Prednisolone 40-60 mg PO OR Hydrocortisone 100-200 mg IV<br>
    ‚Ä¢ Give within first hour<br>
    <br>
    <strong>STEP 4: ADJUNCT THERAPIES</strong><br>
    ‚Ä¢ Magnesium sulfate 2 g IV over 20 minutes<br>
    ‚Ä¢ Consider IV salbutamol/aminophylline if not responding<br>
    <br>
    <strong>STEP 5: ESCALATION</strong><br>
    ‚Ä¢ Consider non-invasive ventilation (BiPAP)<br>
    ‚Ä¢ Prepare for intubation if deteriorating<br>
    ‚Ä¢ ICU consultation
</div>

<!-- CHAPTER 2: DRUG 1 - ADRENALINE (ASTHMA/ANAPHYLAXIS FOCUS) -->
<div class="page-break"></div>
<h2><span class="chapter-number">2</span> Core Drug 1: Adrenaline (Asthma/Anaphylaxis Focus)</h2>

<div class="drug-template">
    <h4>ADRENALINE - LIFESAVER FOR ANAPHYLAXIS & SEVERE ASTHMA</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Non-selective alpha & beta adrenergic agonist
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ <strong class="allergy-red">Alpha-1 (Œ±‚ÇÅ):</strong> Vasoconstriction ‚Üí reduces mucosal edema, increases BP<br>
        ‚Ä¢ <strong class="allergy-red">Beta-1 (Œ≤‚ÇÅ):</strong> Increases heart rate and contractility<br>
        ‚Ä¢ <strong class="allergy-red">Beta-2 (Œ≤‚ÇÇ):</strong> Bronchodilation, stabilizes mast cells, reduces mediator release
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ <strong class="allergy-red">Anaphylaxis</strong> (first-line, immediate treatment)<br>
        ‚Ä¢ Severe asthma exacerbation refractory to nebulized therapy<br>
        ‚Ä¢ Angioedema with airway compromise<br>
        ‚Ä¢ Cardiac arrest (covered in Module 2)<br>
        ‚Ä¢ Croup (racemic adrenaline nebulized)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ None in anaphylaxis (absolute emergency)<br>
        ‚Ä¢ Relative: Hypertension, coronary artery disease, arrhythmias<br>
        ‚Ä¢ Caution with halogenated anesthetics (arrhythmia risk)<br>
        ‚Ä¢ Pheochromocytoma (absolute contraindication for non-emergency use)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="allergy-red">Anaphylaxis IM:</strong> 0.3-0.5 mg IM (1:1000) in anterolateral thigh<br>
        ‚Ä¢ <strong class="allergy-red">Severe asthma IM:</strong> 0.3-0.5 mg IM (1:1000)<br>
        ‚Ä¢ <strong class="allergy-red">Anaphylaxis IV (refractory):</strong> 0.1 mg IV slowly (1:10,000) over 5-10 minutes<br>
        ‚Ä¢ <strong class="allergy-red">Infusion for refractory cases:</strong> 0.05-0.1 mcg/kg/min<br>
        ‚Ä¢ <strong class="allergy-red">Nebulized for croup:</strong> Racemic adrenaline 0.5 mL of 2.25% in 3 mL NS
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="allergy-red">Anaphylaxis IM:</strong> 0.01 mg/kg IM (max 0.3 mg <30kg, 0.5 mg >30kg)<br>
        ‚Ä¢ <strong class="allergy-red">Severe asthma IM:</strong> 0.01 mg/kg IM<br>
        ‚Ä¢ <strong class="allergy-red">Croup nebulized:</strong> 0.05 mL/kg of 2.25% racemic adrenaline (max 0.5 mL)
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="allergy-red">IM (preferred for anaphylaxis):</strong> 1:1000 (1 mg/mL) - anterolateral thigh<br>
        ‚Ä¢ <strong class="allergy-red">IV bolus:</strong> 1:10,000 (0.1 mg/mL) - dilute if needed<br>
        ‚Ä¢ <strong class="allergy-red">Infusion:</strong> Mix 1 mg in 250 mL NS = 4 mcg/mL<br>
        ‚Ä¢ <strong class="allergy-red">Nebulized:</strong> Racemic adrenaline 2.25% solution<br>
        ‚Ä¢ Use within minutes of drawing up (oxidizes quickly)
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Anxiety, tremor, headache<br>
        ‚Ä¢ Tachycardia, palpitations<br>
        ‚Ä¢ Pallor, cold extremities<br>
        ‚Ä¢ Nausea, vomiting
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Ventricular arrhythmias (especially with IV route)<br>
        ‚Ä¢ Myocardial ischemia/infarction<br>
        ‚Ä¢ Severe hypertension ‚Üí cerebral hemorrhage<br>
        ‚Ä¢ Pulmonary edema<br>
        ‚Ä¢ Tissue necrosis with extravasation<br>
        ‚Ä¢ Hyperglycemia
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="allergy-red">Beta-blockers:</strong> Unopposed alpha ‚Üí severe hypertension, bronchospasm<br>
        ‚Ä¢ <strong class="allergy-red">TCAs, MAOIs:</strong> Potentiate effects ‚Üí hypertensive crisis<br>
        ‚Ä¢ <strong class="allergy-red">Halogenated anesthetics:</strong> Increased arrhythmia risk<br>
        ‚Ä¢ <strong class="allergy-red">Digoxin:</strong> Increased arrhythmia risk<br>
        ‚Ä¢ <strong class="allergy-red">Ergot alkaloids:</strong> Extreme vasoconstriction
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="allergy-red">ANAPHYLAXIS GOLDEN RULE:</strong> IM FIRST, NOT IV (IV can cause fatal arrhythmias)<br>
        ‚Ä¢ <strong class="allergy-red">Site matters:</strong> Anterolateral thigh has fastest absorption (vs deltoid)<br>
        ‚Ä¢ <strong class="allergy-red">Repeat doses:</strong> Every 5-10 minutes if no improvement in anaphylaxis<br>
        ‚Ä¢ <strong class="allergy-red">For asthma:</strong> Use only if refractory to nebulized beta-agonists<br>
        ‚Ä¢ <strong class="allergy-red">Auto-injectors:</strong> Epipen = 0.3 mg, Epipen Jr = 0.15 mg<br>
        ‚Ä¢ <strong class="allergy-red">Half-life:</strong> 2-3 minutes - frequent dosing may be needed<br>
        ‚Ä¢ <strong class="allergy-red">Color check:</strong> Clear solution, discard if pink/brown (oxidized)<br>
        ‚Ä¢ <strong class="allergy-red">Beta-blocker patients:</strong> May need glucagon if refractory to adrenaline
    </div>
</div>

<div class="anaphylaxis-alert">
    ‚ö†Ô∏è ANAPHYLAXIS PROTOCOL: ADRENALINE FIRST ‚Üí SUPINE POSITION ‚Üí OXYGEN ‚Üí FLUIDS ‚Üí ANTIHISTAMINES ‚Üí STEROIDS
</div>

<!-- CHAPTER 3: DRUG 2 - AMINOPHYLLINE -->
<div class="page-break"></div>
<h2><span class="chapter-number">3</span> Core Drug 2: Aminophylline</h2>

<div class="drug-template">
    <h4>AMINOPHYLLINE - OLD BUT POTENT BRONCHODILATOR</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Methylxanthine derivative (contains theophylline)
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Non-selective phosphodiesterase inhibitor ‚Üí ‚Üë cAMP ‚Üí bronchodilation<br>
        ‚Ä¢ Adenosine receptor antagonist ‚Üí bronchodilation, cardiac stimulation<br>
        ‚Ä¢ Increases diaphragmatic contractility, reduces fatigue<br>
        ‚Ä¢ Mild anti-inflammatory effects<br>
        ‚Ä¢ Stimulates respiratory center in brainstem
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Severe asthma exacerbation refractory to beta-agonists and steroids<br>
        ‚Ä¢ COPD exacerbation with respiratory failure<br>
        ‚Ä¢ Neonatal apnea (different dosing)<br>
        ‚Ä¢ <strong>Note:</strong> Not first-line, use only when conventional therapy fails
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known hypersensitivity to methylxanthines<br>
        ‚Ä¢ Active peptic ulcer disease<br>
        ‚Ä¢ Uncontrolled seizures<br>
        ‚Ä¢ Severe cardiac arrhythmias<br>
        ‚Ä¢ Severe liver disease<br>
        ‚Ä¢ Use with caution in elderly, heart failure, hypertension
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="respiratory-blue">Loading dose:</strong> 5 mg/kg IV over 20-30 minutes (if not on theophylline)<br>
        ‚Ä¢ <strong class="respiratory-blue">Maintenance infusion:</strong> 0.5 mg/kg/hr<br>
        ‚Ä¢ <strong class="respiratory-blue">Reduce dose:</strong> If patient already on theophylline (check level first)<br>
        ‚Ä¢ <strong class="respiratory-blue">Max loading:</strong> 500 mg, max infusion: 900 mg/day<br>
        ‚Ä¢ <strong class="respiratory-blue">Therapeutic level:</strong> 10-20 mg/L (toxic >20 mg/L)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="respiratory-blue">Loading:</strong> 6 mg/kg IV over 20 minutes<br>
        ‚Ä¢ <strong class="respiratory-blue">Maintenance:</strong><br>
        &nbsp;&nbsp;‚Ä¢ Age 1-9 years: 1 mg/kg/hr<br>
        &nbsp;&nbsp;‚Ä¢ Age 9-12 years: 0.8 mg/kg/hr<br>
        &nbsp;&nbsp;‚Ä¢ Age 12-16 years: 0.7 mg/kg/hr<br>
        ‚Ä¢ <strong class="respiratory-blue">Neonatal apnea:</strong> Different protocol (consult specialist)
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="respiratory-blue">Route:</strong> IV infusion ONLY (never IV push - cardiac arrest risk)<br>
        ‚Ä¢ <strong class="respiratory-blue">Preparation:</strong> Comes as 250 mg/10 mL ampoule (25 mg/mL)<br>
        ‚Ä¢ For loading: Dilute in 100-200 mL D5W or NS, infuse over 20-30 min<br>
        ‚Ä¢ For infusion: Mix in D5W or NS, use infusion pump<br>
        ‚Ä¢ Incompatible with many drugs - use dedicated line
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Nausea, vomiting (common)<br>
        ‚Ä¢ Headache, insomnia<br>
        ‚Ä¢ Palpitations, tachycardia<br>
        ‚Ä¢ Tremor, nervousness<br>
        ‚Ä¢ Diuresis
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Ventricular arrhythmias (including VT, VF)<br>
        ‚Ä¢ Supraventricular tachycardias<br>
        ‚Ä¢ Seizures (especially with levels >40 mg/L)<br>
        ‚Ä¢ Hypotension<br>
        ‚Ä¢ Gastrointestinal bleeding<br>
        ‚Ä¢ Hyperglycemia<br>
        ‚Ä¢ Rhabdomyolysis (rare)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="respiratory-blue">Cimetidine, erythromycin, fluoroquinolones:</strong> Increase levels<br>
        ‚Ä¢ <strong class="respiratory-blue">Phenytoin, rifampin, smoking:</strong> Decrease levels<br>
        ‚Ä¢ <strong class="respiratory-blue">Beta-agonists:</strong> Increased arrhythmia risk<br>
        ‚Ä¢ <strong class="respiratory-blue">Digoxin:</strong> Increased arrhythmia risk<br>
        ‚Ä¢ <strong class="respiratory-blue">Lithium:</strong> Increased lithium excretion<br>
        ‚Ä¢ <strong class="respiratory-blue">Warfarin:</strong> Potentiates effect
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="respiratory-blue">ALWAYS check theophylline level</strong> before loading if possible<br>
        ‚Ä¢ <strong class="respiratory-blue">NO loading dose</strong> if patient already on theophylline<br>
        ‚Ä¢ <strong class="respiratory-blue">Therapeutic window is narrow</strong> (10-20 mg/L)<br>
        ‚Ä¢ <strong class="respiratory-blue">Monitor:</strong> ECG continuously, theophylline levels at 12-24 hrs<br>
        ‚Ä¢ <strong class="respiratory-blue">Toxicity signs:</strong> "Theophylline Toxicity Triad" - Seizures, Arrhythmias, Vomiting<br>
        ‚Ä¢ <strong class="respiratory-blue">Half-life:</strong> Highly variable (3-15 hours) - longer in elderly, liver disease, heart failure<br>
        ‚Ä¢ <strong class="respiratory-blue">Antidote for overdose:</strong> Activated charcoal, consider hemoperfusion for levels >40 mg/L<br>
        ‚Ä¢ <strong class="respiratory-blue">Modern role:</strong> Reserved for ICU patients with refractory asthma
    </div>
</div>

<div class="warning-box">
    <strong>‚ö†Ô∏è AMINOPHYLLINE CAUTION:</strong> This drug has a narrow therapeutic index and significant toxicity. Use only when absolutely necessary and with close monitoring. Most asthma exacerbations respond to beta-agonists and steroids without aminophylline.
</div>

<!-- CHAPTER 4: DRUG 3 - HYDROCORTISONE -->
<div class="page-break"></div>
<h2><span class="chapter-number">4</span> Core Drug 3: Hydrocortisone</h2>

<div class="drug-template">
    <h4>HYDROCORTISONE - RAPID-ACTING STEROID FOR EMERGENCIES</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Short-acting glucocorticoid, mineralocorticoid activity
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Binds glucocorticoid receptors ‚Üí anti-inflammatory effects<br>
        ‚Ä¢ Inhibits phospholipase A‚ÇÇ ‚Üí reduces prostaglandin/leukotriene synthesis<br>
        ‚Ä¢ Stabilizes cell membranes and lysosomal membranes<br>
        ‚Ä¢ Reduces capillary permeability and edema<br>
        ‚Ä¢ Upregulates beta-2 receptors (in asthma)<br>
        ‚Ä¢ Immunosuppressive effects at high doses
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Severe asthma/COPD exacerbation<br>
        ‚Ä¢ Anaphylaxis (second-line after adrenaline)<br>
        ‚Ä¢ Adrenal crisis/insufficiency<br>
        ‚Ä¢ Severe croup<br>
        ‚Ä¢ Septic shock (controversial, usually dexamethasone)<br>
        ‚Ä¢ Acute allergic reactions (severe)<br>
        ‚Ä¢ Acute spinal cord injury (high-dose protocol)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Systemic fungal infections (unless treating adrenal insufficiency)<br>
        ‚Ä¢ Live virus vaccinations (relative)<br>
        ‚Ä¢ Active untreated infections (relative - treat infection concurrently)<br>
        ‚Ä¢ Peptic ulcer disease (relative - use with PPI cover)<br>
        ‚Ä¢ Psychosis (relative)<br>
        ‚Ä¢ Known hypersensitivity
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="steroid-green">Asthma/COPD:</strong> 100-200 mg IV, then 100 mg IV every 6-8 hours<br>
        ‚Ä¢ <strong class="steroid-green">Anaphylaxis:</strong> 200 mg IV/IM single dose<br>
        ‚Ä¢ <strong class="steroid-green">Adrenal crisis:</strong> 100 mg IV bolus, then 200 mg/24 hrs continuous infusion<br>
        ‚Ä¢ <strong class="steroid-green">Septic shock:</strong> 50 mg IV every 6 hours (if indicated)<br>
        ‚Ä¢ <strong class="steroid-green">Spinal cord injury:</strong> 30 mg/kg IV over 15 min, then 5.4 mg/kg/hr √ó 23 hrs
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="steroid-green">Asthma:</strong> 2 mg/kg IV bolus (max 100 mg), then 0.5-1 mg/kg every 6 hours<br>
        ‚Ä¢ <strong class="steroid-green">Anaphylaxis:</strong> 2-4 mg/kg IV/IM (max 100 mg)<br>
        ‚Ä¢ <strong class="steroid-green">Croup:</strong> 2 mg/kg IV/IM (usually dexamethasone preferred)<br>
        ‚Ä¢ <strong class="steroid-green">Adrenal crisis:</strong> 1-2 mg/kg IV bolus, then 25-150 mg/m¬≤/day
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="steroid-green">Routes:</strong> IV, IM, oral (though not for emergencies)<br>
        ‚Ä¢ <strong class="steroid-green">Preparation:</strong> Comes as 100 mg vial (powder for reconstitution)<br>
        ‚Ä¢ Reconstitute with 2 mL bacteriostatic water = 50 mg/mL<br>
        ‚Ä¢ For IV: Can give undiluted over 1 minute or in 50-100 mL bag over 15-30 min<br>
        ‚Ä¢ Compatible with most IV solutions, but check specific compatibility
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Hyperglycemia (monitor blood glucose)<br>
        ‚Ä¢ Fluid retention, hypertension<br>
        ‚Ä¢ Mood changes, insomnia<br>
        ‚Ä¢ Increased appetite<br>
        ‚Ä¢ Hypokalemia (mineralocorticoid effect)<br>
        ‚Ä¢ Peptic ulcer risk (use PPI prophylaxis)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Adrenal suppression with prolonged use (>2-3 weeks)<br>
        ‚Ä¢ Opportunistic infections<br>
        ‚Ä¢ Osteoporosis with long-term use<br>
        ‚Ä¢ Avascular necrosis<br>
        ‚Ä¢ Cataracts, glaucoma<br>
        ‚Ä¢ Myopathy (proximal muscle weakness)<br>
        ‚Ä¢ Growth suppression in children
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="steroid-green">NSAIDs:</strong> Increased GI ulcer risk<br>
        ‚Ä¢ <strong class="steroid-green">Anticoagulants:</strong> May alter response<br>
        ‚Ä¢ <strong class="steroid-green">Antidiabetics/insulin:</strong> Increased insulin requirements<br>
        ‚Ä¢ <strong class="steroid-green">Phenytoin, rifampin:</strong> Increased steroid metabolism<br>
        ‚Ä¢ <strong class="steroid-green">Ketoconazole, erythromycin:</strong> Increased steroid levels<br>
        ‚Ä¢ <strong class="steroid-green">Diuretics:</strong> Increased potassium loss
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="steroid-green">Onset of action:</strong> 1-2 hours, peak 4-6 hours<br>
        ‚Ä¢ <strong class="steroid-green">In asthma:</strong> Give within first hour of presentation<br>
        ‚Ä¢ <strong class="steroid-green">IV vs oral:</strong> Equally effective for asthma, use oral if patient can swallow<br>
        ‚Ä¢ <strong class="steroid-green">Duration:</strong> Usually 5-7 days for asthma, no need to taper if <2 weeks<br>
        ‚Ä¢ <strong class="steroid-green">Adrenal crisis:</strong> Give BEFORE diagnostic tests if suspected<br>
        ‚Ä¢ <strong class="steroid-green">Stress dosing:</strong> Patients on chronic steroids need increased doses during illness<br>
        ‚Ä¢ <strong class="steroid-green">Solu-Cortef¬Æ:</strong> Brand name for IV hydrocortisone sodium succinate<br>
        ‚Ä¢ <strong class="steroid-green">Mineralocorticoid effect:</strong> Significant - can cause hypokalemia, hypertension
    </div>
</div>

<div class="clinical-pearl">
    <strong>üß† STEROID EQUIVALENCIES:</strong><br>
    ‚Ä¢ Hydrocortisone 20 mg = Prednisolone 5 mg = Dexamethasone 0.75 mg = Methylprednisolone 4 mg<br>
    ‚Ä¢ <em>Hydrocortisone has both glucocorticoid and mineralocorticoid activity; others are primarily glucocorticoid</em>
</div>

<!-- CHAPTER 5: DRUG 4 - DEXAMETHASONE -->
<div class="page-break"></div>
<h2><span class="chapter-number">5</span> Core Drug 4: Dexamethasone</h2>

<div class="drug-template">
    <h4>DEXAMETHASONE - POTENT LONG-ACTING STEROID</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Long-acting glucocorticoid, minimal mineralocorticoid activity
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Potent glucocorticoid receptor agonist (25-30 times more potent than hydrocortisone)<br>
        ‚Ä¢ Strong anti-inflammatory and immunosuppressive effects<br>
        ‚Ä¢ Stabilizes cell membranes, reduces capillary permeability<br>
        ‚Ä¢ Inhibits cytokine production and inflammatory cell migration<br>
        ‚Ä¢ Reduces cerebral edema (lowers ICP)<br>
        ‚Ä¢ Antiemetic properties (acts on chemoreceptor trigger zone)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Croup (first-line treatment)<br>
        ‚Ä¢ Asthma/COPD exacerbation (single dose alternative)<br>
        ‚Ä¢ Cerebral edema (tumor-related, not traumatic)<br>
        ‚Ä¢ Chemotherapy-induced nausea/vomiting<br>
        ‚Ä¢ Spinal cord compression<br>
        ‚Ä¢ Bacterial meningitis (controversial, adjunct to antibiotics)<br>
        ‚Ä¢ Severe COVID-19 pneumonia (evidence-based)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Systemic fungal infections<br>
        ‚Ä¢ Cerebral malaria (increased mortality)<br>
        ‚Ä¢ Active untreated infections (relative)<br>
        ‚Ä¢ Live virus vaccines (relative)<br>
        ‚Ä¢ Known hypersensitivity<br>
        ‚Ä¢ Psychosis (relative)<br>
        ‚Ä¢ Avoid in traumatic brain injury (increased mortality)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="steroid-green">Croup:</strong> 0.6 mg/kg IM/IV (max 10 mg) single dose<br>
        ‚Ä¢ <strong class="steroid-green">Asthma/COPD:</strong> 6-10 mg IV/IM/PO single dose<br>
        ‚Ä¢ <strong class="steroid-green">Cerebral edema:</strong> 10 mg IV bolus, then 4 mg IV every 6 hours<br>
        ‚Ä¢ <strong class="steroid-green">COVID-19:</strong> 6 mg IV/PO daily for up to 10 days<br>
        ‚Ä¢ <strong class="steroid-green">Spinal cord compression:</strong> 10 mg IV bolus, then 4 mg every 6 hours<br>
        ‚Ä¢ <strong class="steroid-green">Chemotherapy N/V:</strong> 8-20 mg IV before chemo
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="steroid-green">Croup:</strong> 0.6 mg/kg IM/IV/PO (max 10 mg) single dose<br>
        ‚Ä¢ <strong class="steroid-green">Asthma:</strong> 0.3-0.6 mg/kg IV/IM/PO (max 10 mg) single dose<br>
        ‚Ä¢ <strong class="steroid-green">Bacterial meningitis:</strong> 0.15 mg/kg IV every 6 hours √ó 4 days<br>
        ‚Ä¢ <strong class="steroid-green">Cerebral edema:</strong> 0.5-1 mg/kg IV loading, then 0.25-0.5 mg/kg every 6 hours
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="steroid-green">Routes:</strong> IV, IM, oral (excellent bioavailability PO)<br>
        ‚Ä¢ <strong class="steroid-green">Preparation:</strong> Comes as 4 mg/mL ampoule, 10 mg/mL vial<br>
        ‚Ä¢ For IV: Can give undiluted over 1-2 minutes<br>
        ‚Ä¢ For infusion: Dilute in 50-100 mL D5W or NS, infuse over 15-30 minutes<br>
        ‚Ä¢ Oral tablets: 0.5 mg, 0.75 mg, 4 mg strengths available<br>
        ‚Ä¢ Compatible with most IV solutions
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Hyperglycemia (less than hydrocortisone)<br>
        ‚Ä¢ Insomnia, mood changes<br>
        ‚Ä¢ Increased appetite<br>
        ‚Ä¢ Fluid retention (minimal compared to hydrocortisone)<br>
        ‚Ä¢ Hypokalemia (minimal)<br>
        ‚Ä¢ Peptic ulcer risk (use PPI if prolonged)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Adrenal suppression (with prolonged use)<br>
        ‚Ä¢ Opportunistic infections<br>
        ‚Ä¢ Osteoporosis<br>
        ‚Ä¢ Avascular necrosis<br>
        ‚Ä¢ Cataracts<br>
        ‚Ä¢ Myopathy<br>
        ‚Ä¢ Growth suppression in children<br>
        ‚Ä¢ Psychosis (high doses)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="steroid-green">Anticoagulants:</strong> May alter response<br>
        ‚Ä¢ <strong class="steroid-green">Antidiabetics/insulin:</strong> Increased requirements<br>
        ‚Ä¢ <strong class="steroid-green">Phenytoin, rifampin:</strong> Increased metabolism<br>
        ‚Ä¢ <strong class="steroid-green">Ketoconazole:</strong> Increased levels<br>
        ‚Ä¢ <strong class="steroid-green">NSAIDs:</strong> Increased GI risk<br>
        ‚Ä¢ <strong class="steroid-green">Vaccines:</strong> Reduced immune response
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="steroid-green">Long half-life:</strong> 36-72 hours - single dose often sufficient<br>
        ‚Ä¢ <strong class="steroid-green">For croup:</strong> Single dose reduces hospitalization, ICU admissions<br>
        ‚Ä¢ <strong class="steroid-green">Oral bioavailability:</strong> Excellent (80-90%) - PO = IV for most indications<br>
        ‚Ä¢ <strong class="steroid-green">Minimal mineralocorticoid effect</strong> - less fluid retention than hydrocortisone<br>
        ‚Ä¢ <strong class="steroid-green">Onset:</strong> 1-2 hours, duration 36-72 hours<br>
        ‚Ä¢ <strong class="steroid-green">COVID-19:</strong> RECOVERY trial showed mortality benefit in ventilated patients<br>
        ‚Ä¢ <strong class="steroid-green">Tapering:</strong> Needed if used >2-3 weeks due to adrenal suppression<br>
        ‚Ä¢ <strong class="steroid-green">Cost-effective:</strong> Often cheaper than multiple hydrocortisone doses
    </div>
</div>

<div class="clinical-pearl">
    <strong>üß† DEXAMETHASONE FOR CROUP:</strong> Single dose reduces symptoms within 2 hours, effects last 3-4 days. PO administration is as effective as IM/IV and avoids needle sticks in children.
</div>

<!-- CHAPTER 6: DRUG 5 - MAGNESIUM SULFATE (ASTHMA) -->
<div class="page-break"></div>
<h2><span class="chapter-number">6</span> Core Drug 5: Magnesium Sulfate (Asthma Focus)</h2>

<div class="drug-template">
    <h4>MAGNESIUM SULFATE - BRONCHODILATOR ADJUNCT</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Electrolyte, natural calcium channel blocker
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Natural calcium antagonist ‚Üí smooth muscle relaxation (bronchial, vascular)<br>
        ‚Ä¢ Inhibits acetylcholine release at neuromuscular junction<br>
        ‚Ä¢ Reduces histamine release from mast cells<br>
        ‚Ä¢ Anti-inflammatory effects<br>
        ‚Ä¢ Stabilizes cell membranes<br>
        ‚Ä¢ Enhances beta-2 agonist effects (synergistic)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ <strong class="respiratory-blue">Severe acute asthma</strong> refractory to standard therapy<br>
        ‚Ä¢ Life-threatening asthma exacerbations<br>
        ‚Ä¢ Acute COPD exacerbation (evidence less strong)<br>
        ‚Ä¢ Torsades de pointes (covered in Module 2)<br>
        ‚Ä¢ Eclampsia/pre-eclampsia (different dosing)<br>
        ‚Ä¢ Hypomagnesemia
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Myasthenia gravis (can worsen weakness)<br>
        ‚Ä¢ Heart block (without pacemaker)<br>
        ‚Ä¢ Severe renal impairment (CrCl <30 mL/min)<br>
        ‚Ä¢ Hypermagnesemia<br>
        ‚Ä¢ Concurrent calcium channel blockers (relative - additive effects)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="respiratory-blue">Severe asthma:</strong> 2 g IV over 20 minutes single dose<br>
        ‚Ä¢ <strong class="respiratory-blue">Life-threatening asthma:</strong> Consider 2 g IV, may repeat once<br>
        ‚Ä¢ <strong class="respiratory-blue">Infusion (rarely needed):</strong> 1-2 g/hr after loading dose<br>
        ‚Ä¢ <strong class="respiratory-blue">Nebulized (alternative):</strong> 500 mg nebulized (evidence limited)<br>
        ‚Ä¢ <strong class="respiratory-blue">Max single dose:</strong> 4 g, max daily: 30-40 g (but usually 2-4 g total)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="respiratory-blue">Severe asthma:</strong> 25-50 mg/kg IV over 20 minutes (max 2 g)<br>
        ‚Ä¢ <strong class="respiratory-blue">May repeat:</strong> Once in 20-30 minutes if no improvement<br>
        ‚Ä¢ <strong class="respiratory-blue">Infusion:</strong> 20-50 mg/kg/hr (max 2 g/hr) if continuous needed<br>
        ‚Ä¢ <strong class="respiratory-blue">Nebulized:</strong> 150 mg nebulized (limited evidence)
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="respiratory-blue">Routes:</strong> IV (preferred), nebulized (alternative)<br>
        ‚Ä¢ <strong class="respiratory-blue">Preparation:</strong> Available as 1 g/2 mL (50%), 2 g/10 mL (20%), 4 g/8 mL (50%)<br>
        ‚Ä¢ For IV infusion: Dilute to ‚â§20% concentration (200 mg/mL)<br>
        ‚Ä¢ For 2 g dose: Dilute in 100 mL D5W or NS, infuse over 20 minutes<br>
        ‚Ä¢ For nebulized: Use isotonic solution (no bronchoconstriction)
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Flushing, warmth sensation (common)<br>
        ‚Ä¢ Nausea, vomiting<br>
        ‚Ä¢ Headache, dizziness<br>
        ‚Ä¢ Muscle weakness, lethargy<br>
        ‚Ä¢ Injection site pain/phlebitis
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Hypotension (vasodilation)<br>
        ‚Ä¢ Bradycardia, heart block<br>
        ‚Ä¢ Respiratory depression/arrest (high levels)<br>
        ‚Ä¢ Loss of deep tendon reflexes (>4-5 mEq/L)<br>
        ‚Ä¢ Cardiac arrest (>10-15 mEq/L)<br>
        ‚Ä¢ Hypocalcemia (displaces calcium)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="respiratory-blue">Neuromuscular blockers:</strong> Potentiates effect<br>
        ‚Ä¢ <strong class="respiratory-blue">Calcium channel blockers:</strong> Additive hypotension, bradycardia<br>
        ‚Ä¢ <strong class="respiratory-blue">Digoxin:</strong> May worsen heart block<br>
        ‚Ä¢ <strong class="respiratory-blue">Aminoglycosides:</strong> Potentiates neuromuscular blockade<br>
        ‚Ä¢ <strong class="respiratory-blue">Calcium:</strong> Antagonizes effects
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="respiratory-blue">Onset:</strong> Bronchodilation within 10-15 minutes, peaks at 30-60 minutes<br>
        ‚Ä¢ <strong class="respiratory-blue">Duration:</strong> 2-4 hours<br>
        ‚Ä¢ <strong class="respiratory-blue">Monitor:</strong> BP, reflexes, respiratory rate during infusion<br>
        ‚Ä¢ <strong class="respiratory-blue">Therapeutic level for asthma:</strong> 4-6 mg/dL (2-3 mmol/L)<br>
        ‚Ä¢ <strong class="respiratory-blue">Normal magnesium:</strong> 1.5-2.5 mg/dL (0.6-1 mmol/L)<br>
        ‚Ä¢ <strong class="respiratory-blue">Check level</strong> 2 hours after dose if renal impairment or prolonged use<br>
        ‚Ä¢ <strong class="respiratory-blue">Antidote:</strong> Calcium gluconate/chloride 1 g IV for toxicity<br>
        ‚Ä¢ <strong class="respiratory-blue">Evidence:</strong> Most benefit in severe asthma (FEV‚ÇÅ <25-30% predicted)<br>
        ‚Ä¢ <strong class="respiratory-blue">Mechanism in asthma:</strong> Works even if beta-receptors downregulated
    </div>
</div>

<div class="clinical-pearl">
    <strong>üß† MAGNESIUM IN ASTHMA:</strong> Consider when patient has:<br>
    1. Life-threatening features (silent chest, exhaustion, cyanosis)<br>
    2. Poor response to 3 doses of nebulized beta-agonists<br>
    3. FEV‚ÇÅ or PEF <30% predicted<br>
    4. Rising PaCO‚ÇÇ (ominous sign)
</div>

<!-- CHAPTER 7: DRUG 6 - SALBUTAMOL INJECTION -->
<div class="page-break"></div>
<h2><span class="chapter-number">7</span> Core Drug 6: Salbutamol Injection (Where Applicable)</h2>

<div class="drug-template">
    <h4>SALBUTAMOL (ALBUTEROL) INJECTION - RESERVED FOR CRITICAL CASES</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Selective beta-2 adrenergic agonist
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Selective beta-2 receptor agonist ‚Üí bronchodilation<br>
        ‚Ä¢ Stimulates adenylate cyclase ‚Üí ‚Üë cAMP ‚Üí smooth muscle relaxation<br>
        ‚Ä¢ Also has some beta-1 activity at higher doses (tachycardia)<br>
        ‚Ä¢ Enhances mucociliary clearance<br>
        ‚Ä¢ Inhibits mast cell mediator release<br>
        ‚Ä¢ May reduce pulmonary vascular resistance
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ <strong class="respiratory-blue">Severe asthma exacerbation</strong> when nebulized route ineffective<br>
        ‚Ä¢ Status asthmaticus refractory to inhaled therapy<br>
        ‚Ä¢ Hyperkalemia (promotes intracellular potassium shift)<br>
        ‚Ä¢ Preterm labor (tocolysis - different dosing)<br>
        ‚Ä¢ <strong>Note:</strong> IV route is HIGH-RISK, use only when absolutely necessary
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Tachyarrhythmias<br>
        ‚Ä¢ Idiopathic hypertrophic subaortic stenosis (IHSS)<br>
        ‚Ä¢ Hypersensitivity to beta-agonists<br>
        ‚Ä¢ Uncontrolled hyperthyroidism<br>
        ‚Ä¢ Severe coronary artery disease<br>
        ‚Ä¢ Relative: Hypertension, diabetes, seizure disorders
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="respiratory-blue">IV bolus:</strong> 4 mcg/kg over 5-10 minutes (rarely used)<br>
        ‚Ä¢ <strong class="respiratory-blue">IV infusion:</strong> Start 5-20 mcg/min, titrate to effect<br>
        ‚Ä¢ <strong class="respiratory-blue">Typical range:</strong> 5-40 mcg/min<br>
        ‚Ä¢ <strong class="respiratory-blue">Max dose:</strong> 40-60 mcg/min (higher risks side effects)<br>
        ‚Ä¢ <strong class="respiratory-blue">For hyperkalemia:</strong> 10-20 mg nebulized (preferred over IV)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="respiratory-blue">IV bolus:</strong> 2.5-5 mcg/kg over 5-10 minutes<br>
        ‚Ä¢ <strong class="respiratory-blue">IV infusion:</strong> Start 1-2 mcg/kg/min, titrate up to 10 mcg/kg/min<br>
        ‚Ä¢ <strong class="respiratory-blue">Max:</strong> 10 mcg/kg/min (with extreme caution)<br>
        ‚Ä¢ Use only in ICU setting with continuous monitoring
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="respiratory-blue">Routes:</strong> IV infusion (preferred over bolus), subcutaneous, IM<br>
        ‚Ä¢ <strong class="respiratory-blue">Preparation:</strong> Comes as 1 mg/mL (1:1000) ampoule<br>
        ‚Ä¢ For infusion: Mix 5 mg in 500 mL D5W or NS = 10 mcg/mL<br>
        ‚Ä¢ Alternative: 10 mg in 500 mL = 20 mcg/mL<br>
        ‚Ä¢ Must use infusion pump<br>
        ‚Ä¢ Compatible with most IV solutions
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Tachycardia, palpitations (beta-1 effect at high doses)<br>
        ‚Ä¢ Tremor, anxiety, nervousness<br>
        ‚Ä¢ Headache, dizziness<br>
        ‚Ä¢ Hypokalemia (beta-2 mediated intracellular shift)<br>
        ‚Ä¢ Hyperglycemia (especially in diabetics)<br>
        ‚Ä¢ Muscle cramps
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Ventricular arrhythmias (VT, VF)<br>
        ‚Ä¢ Myocardial ischemia/infarction<br>
        ‚Ä¢ Severe hypokalemia ‚Üí arrhythmias<br>
        ‚Ä¢ Pulmonary edema (rare)<br>
        ‚Ä¢ Lactic acidosis (with high doses)<br>
        ‚Ä¢ Paradoxical bronchospasm (rare)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="respiratory-blue">Beta-blockers:</strong> Antagonizes effect (avoid non-selective beta-blockers in asthma)<br>
        ‚Ä¢ <strong class="respiratory-blue">Digoxin:</strong> Increased arrhythmia risk<br>
        ‚Ä¢ <strong class="respiratory-blue">MAOIs, TCAs:</strong> Potentiates cardiovascular effects<br>
        ‚Ä¢ <strong class="respiratory-blue">Diuretics:</strong> Increased hypokalemia risk<br>
        ‚Ä¢ <strong class="respiratory-blue">Theophylline/aminophylline:</strong> Increased arrhythmia risk<br>
        ‚Ä¢ <strong class="respiratory-blue">Corticosteroids:</strong> Increased hypokalemia risk
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="respiratory-blue">IV salbutamol is HIGH-RISK</strong> - use only in ICU with continuous monitoring<br>
        ‚Ä¢ <strong class="respiratory-blue">Monitor:</strong> ECG continuously, potassium, glucose, lactate<br>
        ‚Ä¢ <strong class="respiratory-blue">Hypokalemia:</strong> Can be severe - check K‚Å∫ every 2-4 hours, replace aggressively<br>
        ‚Ä¢ <strong class="respiratory-blue">Tachycardia:</strong> Often limits dose escalation<br>
        ‚Ä¢ <strong class="respiratory-blue">Half-life:</strong> IV: 4-6 hours<br>
        ‚Ä¢ <strong class="respiratory-blue">Onset:</strong> Immediate, duration 4-6 hours<br>
        ‚Ä¢ <strong class="respiratory-blue">For hyperkalemia:</strong> 10-20 mg nebulized works within 30 minutes<br>
        ‚Ä¢ <strong class="respiratory-blue">Modern practice:</strong> IV route rarely used; prefer continuous nebulization<br>
        ‚Ä¢ <strong class="respiratory-blue">Tolerance:</strong> Tachyphylaxis develops with continuous infusion >24 hours
    </div>
</div>

<div class="warning-box">
    <strong>‚ö†Ô∏è IV SALBUTAMOL WARNING:</strong> This route carries significant cardiac risks. Consider continuous nebulized salbutamol (10-15 mg/hr) as a safer alternative. Reserve IV route for patients who cannot generate adequate inspiratory flow for nebulization.
</div>

<!-- CHAPTER 8: DRUG 7 - IPRATROPIUM (INJECTABLE OVERVIEW) -->
<div class="page-break"></div>
<h2><span class="chapter-number">8</span> Core Drug 7: Ipratropium (Injectable Overview)</h2>

<div class="drug-template">
    <h4>IPRATROPIUM - ANTICHOLINERGIC BRONCHODILATOR</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Quaternary ammonium anticholinergic, muscarinic antagonist
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Competitive inhibition of acetylcholine at muscarinic (M‚ÇÉ) receptors<br>
        ‚Ä¢ Blocks vagally-mediated bronchoconstriction<br>
        ‚Ä¢ Reduces mucus secretion<br>
        ‚Ä¢ Quaternary structure ‚Üí minimal systemic absorption when inhaled<br>
        ‚Ä¢ No CNS effects (does not cross blood-brain barrier)<br>
        ‚Ä¢ Synergistic with beta-agonists (different mechanisms)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Acute asthma exacerbation (combined with beta-agonist)<br>
        ‚Ä¢ COPD exacerbation (especially with significant bronchospasm)<br>
        ‚Ä¢ Rhinorrhea (intranasal formulation)<br>
        ‚Ä¢ <strong>Note:</strong> Primarily used via inhalation; IV route exists but rarely used<br>
        ‚Ä¢ Premedication to reduce secretions (different drug: glycopyrrolate preferred)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Hypersensitivity to ipratropium or atropine derivatives<br>
        ‚Ä¢ Narrow-angle glaucoma (for nebulized - can get in eyes)<br>
        ‚Ä¢ Bladder neck obstruction (relative)<br>
        ‚Ä¢ Myasthenia gravis (relative)<br>
        ‚Ä¢ Peanut or soy allergy (some formulations contain soya lecithin)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="respiratory-blue">Nebulized (standard):</strong> 0.5 mg (2.5 mL of 0.02%) every 4-6 hours<br>
        ‚Ä¢ <strong class="respiratory-blue">Severe exacerbation:</strong> 0.5 mg every 20 minutes √ó 3, then every 2-4 hours<br>
        ‚Ä¢ <strong class="respiratory-blue">MDI:</strong> 2 puffs (36 mcg) every 4-6 hours<br>
        ‚Ä¢ <strong class="respiratory-blue">IV (rare):</strong> 0.1-0.4 mg IV (limited data)<br>
        ‚Ä¢ <strong class="respiratory-blue">Intranasal:</strong> 0.03% or 0.06% solution for rhinorrhea
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="respiratory-blue">Nebulized:</strong> 0.25 mg (1.25 mL of 0.02%) for <12 years, 0.5 mg for >12 years<br>
        ‚Ä¢ <strong class="respiratory-blue">Severe asthma:</strong> 0.25-0.5 mg every 20 minutes √ó 3<br>
        ‚Ä¢ <strong class="respiratory-blue">MDI:</strong> 1-2 puffs every 4-6 hours<br>
        ‚Ä¢ <strong class="respiratory-blue">IV:</strong> Not recommended (insufficient data)
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="respiratory-blue">Primary route:</strong> Nebulized (preferred), MDI with spacer<br>
        ‚Ä¢ <strong class="respiratory-blue">Preparation:</strong> Unit dose vials: 0.5 mg/2.5 mL (0.02%)<br>
        ‚Ä¢ For nebulization: Use undiluted or dilute with NS to 3-4 mL total volume<br>
        ‚Ä¢ Often combined with salbutamol in same nebulizer ("combi-neb")<br>
        ‚Ä¢ IV formulation exists but rarely used in clinical practice
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Dry mouth, bitter taste<br>
        ‚Ä¢ Headache, dizziness<br>
        ‚Ä¢ Cough (paradoxical - from dry airways)<br>
        ‚Ä¢ Palpitations (usually from combined beta-agonist)<br>
        ‚Ä¢ Blurred vision if nebulized solution reaches eyes<br>
        ‚Ä¢ Urinary retention (rare with inhaled route)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Worsening of narrow-angle glaucoma (if nebulized solution reaches eyes)<br>
        ‚Ä¢ Anaphylaxis (rare)<br>
        ‚Ä¢ Paradoxical bronchospasm (very rare)<br>
        ‚Ä¢ Tachycardia (with systemic absorption)<br>
        ‚Ä¢ Urinary retention (especially in elderly men with BPH)<br>
        ‚Ä¢ Acute angle-closure glaucoma (ocular exposure)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="respiratory-blue">Other anticholinergics:</strong> Additive effects (atropine, TCAs, antihistamines)<br>
        ‚Ä¢ <strong class="respiratory-blue">Beta-agonists:</strong> Synergistic bronchodilation<br>
        ‚Ä¢ <strong class="respiratory-blue">Potassium chloride:</strong> May reduce effect (theoretical)<br>
        ‚Ä¢ Minimal significant interactions due to low systemic absorption
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="respiratory-blue">Onset:</strong> 5-15 minutes, peak 1-2 hours, duration 4-6 hours<br>
        ‚Ä¢ <strong class="respiratory-blue">Synergy:</strong> Works better with beta-agonists than alone<br>
        ‚Ä¢ <strong class="respiratory-blue">COPD vs Asthma:</strong> More effective in COPD (vagal tone more important)<br>
        ‚Ä¢ <strong class="respiratory-blue">Eye protection:</strong> Use mouthpiece, not mask, to avoid ocular exposure<br>
        ‚Ä¢ <strong class="respiratory-blue">No tachyphylaxis</strong> - unlike beta-agonists<br>
        ‚Ä¢ <strong class="respiratory-blue">Quaternary structure:</strong> Minimal systemic effects when inhaled<br>
        ‚Ä¢ <strong class="respiratory-blue">Combination products:</strong> DuoNeb¬Æ (ipratropium + albuterol) convenient<br>
        ‚Ä¢ <strong class="respiratory-blue">Storage:</strong> Protect from light, use within 24 hours of opening
    </div>
</div>

<!-- CHAPTER 9: ANAPHYLAXIS MANAGEMENT PROTOCOL -->
<div class="page-break"></div>
<h2><span class="chapter-number">9</span> Anaphylaxis Management Protocol</h2>

<div class="anaphylaxis-alert">
    ‚ö†Ô∏è ANAPHYLAXIS IS A MEDICAL EMERGENCY - ACT IMMEDIATELY!
</div>

<h3>9.1 Step-by-Step Anaphylaxis Management</h3>

<div class="breathing-algorithm">
    <strong>STEP 1: RECOGNITION (Seconds)</strong><br>
    ‚Ä¢ Sudden onset (minutes to hours)<br>
    ‚Ä¢ Skin/mucosal: Hives, itching, flushing, angioedema<br>
    ‚Ä¢ Respiratory: Stridor, wheeze, dyspnea, hypoxemia<br>
    ‚Ä¢ Cardiovascular: Hypotension, tachycardia, collapse<br>
    ‚Ä¢ Gastrointestinal: Cramping, vomiting, diarrhea<br>
    <br>
    <strong>STEP 2: IMMEDIATE ACTIONS (0-2 minutes)</strong><br>
    ‚Ä¢ Remove trigger if possible (stop IV medication, remove sting)<br>
    ‚Ä¢ Call for HELP (crash team, senior support)<br>
    ‚Ä¢ Position: Supine (or left lateral if pregnant)<br>
    ‚Ä¢ High-flow oxygen: 15 L/min via non-rebreather mask<br>
    ‚Ä¢ Assess airway: Prepare for intubation if stridor present<br>
    <br>
    <strong>STEP 3: ADRENALINE (Within 5 minutes)</strong><br>
    ‚Ä¢ IM Adrenaline: 0.3-0.5 mg (1:1000) in anterolateral thigh<br>
    ‚Ä¢ Repeat every 5-10 minutes if no improvement<br>
    ‚Ä¢ IV Adrenaline: Only if refractory (0.1 mg of 1:10,000 over 5-10 min)<br>
    <br>
    <strong>STEP 4: FLUID RESUSCITATION (Concurrent)</strong><br>
    ‚Ä¢ Wide-bore IV access (x2 if possible)<br>
    ‚Ä¢ Normal saline: 500-1000 mL bolus (child: 20 mL/kg)<br>
    ‚Ä¢ Repeat if hypotensive<br>
    ‚Ä¢ Consider colloid if massive fluid requirement<br>
    <br>
    <strong>STEP 5: SECOND-LINE MEDICATIONS (After adrenaline)</strong><br>
    ‚Ä¢ Chlorphenamine: 10 mg IV/IM (child: 0.2 mg/kg)<br>
    ‚Ä¢ Hydrocortisone: 200 mg IV (child: 2-4 mg/kg)<br>
    ‚Ä¢ Salbutamol neb: If bronchospasm prominent<br>
    <br>
    <strong>STEP 6: REFRACTORY CASES (ICU management)</strong><br>
    ‚Ä¢ Adrenaline infusion: 0.05-0.1 mcg/kg/min<br>
    ‚Ä¢ Glucagon: 1-2 mg IV if on beta-blockers<br>
    ‚Ä¢ Vasopressin: Consider if catecholamine-resistant<br>
    ‚Ä¢ Methylene blue: For refractory vasodilation (rare)<br>
    ‚Ä¢ ECMO: Consider for catastrophic cases
</div>

<h3>9.2 Special Considerations in Anaphylaxis</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th>Special Situation</th>
            <th>Consideration</th>
            <th>Action</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Beta-blocker use</strong></td>
            <td>May be refractory to adrenaline</td>
            <td>Add glucagon 1-2 mg IV, consider atropine for bradycardia</td>
        </tr>
        <tr>
            <td><strong>ACE inhibitor use</strong></td>
            <td>Increased bradykinin ‚Üí angioedema risk</td>
            <td>Consider icatibant (bradykinin antagonist) for ACEI-induced angioedema</td>
        </tr>
        <tr>
            <td><strong>Pregnancy</strong></td>
            <td>Left lateral position, fetal monitoring</td>
            <td>Same adrenaline dosing, monitor fetus after stabilization</td>
        </tr>
        <tr>
            <td><strong>Mastocytosis</strong></td>
            <td>Extreme sensitivity, may need higher doses</td>
            <td>Titrate adrenaline carefully, consider ICU early</td>
        </tr>
        <tr>
            <td><strong>Idiopathic</strong></td>
            <td>No trigger identified</td>
            <td>Same treatment, refer to allergy clinic</td>
        </tr>
        <tr>
            <td><strong>Biphasic reaction</strong></td>
            <td>Recurrence 4-8 hours after initial treatment</td>
            <td>Observe 6-8 hours minimum, consider longer if severe</td>
        </tr>
    </tbody>
</table>

<!-- CHAPTER 10: ASTHMA VS COPD MANAGEMENT -->
<div class="page-break"></div>
<h2><span class="chapter-number">10</span> Asthma vs COPD: Emergency Management Differences</h2>

<div class="definition-box">
    <strong>Key Difference:</strong> Asthma is reversible airway inflammation; COPD is progressive, not fully reversible airflow limitation. Emergency management overlaps but has important differences.
</div>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 25%;">Aspect</th>
            <th>Acute Severe Asthma</th>
            <th>COPD Exacerbation</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>First-line bronchodilator</strong></td>
            <td>Salbutamol (beta-2 agonist)</td>
            <td>Combination: Salbutamol + Ipratropium</td>
        </tr>
        <tr>
            <td><strong>Corticosteroid dose</strong></td>
            <td>Higher (e.g., Prednisolone 40-60 mg)</td>
            <td>Lower (e.g., Prednisolone 30 mg)</td>
        </tr>
        <tr>
            <td><strong>Steroid duration</strong></td>
            <td>5-7 days (no taper if <2 weeks)</td>
            <td>5 days (evidence for shorter course)</td>
        </tr>
        <tr>
            <td><strong>Magnesium sulfate</strong></td>
            <td>Strong evidence for severe cases</td>
            <td>Weak evidence, not routine</td>
        </tr>
        <tr>
            <td><strong>Aminophylline</strong></td>
            <td>Consider in refractory cases</td>
            <td>Not recommended (increased side effects)</td>
        </tr>
        <tr>
            <td><strong>Antibiotics</strong></td>
            <td>Only if evidence of infection</td>
            <td>Often indicated (increased sputum purulence)</td>
        </tr>
        <tr>
            <td><strong>Oxygen target</strong></td>
            <td>94-98% (avoid hypercapnia)</td>
            <td>88-92% (controlled oxygen therapy)</td>
        </tr>
        <tr>
            <td><strong>Non-invasive ventilation</strong></td>
            <td>Consider in life-threatening cases</td>
            <td>First-line for respiratory failure</td>
        </tr>
        <tr>
            <td><strong>ICU referral</strong></td>
            <td>Silent chest, exhaustion, rising PaCO‚ÇÇ</td>
            <td>pH <7.25 despite NIV, confusion, worsening gas exchange</td>
        </tr>
    </tbody>
</table>

<!-- APPENDIX: QUICK REFERENCE GUIDES -->
<div class="page-break"></div>
<h2>Appendix: Quick Reference Guides</h2>

<h3>Severe Asthma Treatment Protocol</h3>

<div class="asthma-box">
    <strong>üîµ SEVERE ASTHMA (PEF 40-69% predicted):</strong><br>
    ‚Ä¢ Oxygen to maintain SpO‚ÇÇ 94-98%<br>
    ‚Ä¢ Salbutamol 5 mg + Ipratropium 0.5 mg neb back-to-back<br>
    ‚Ä¢ Repeat nebs every 20 minutes √ó 3 if needed<br>
    ‚Ä¢ Prednisolone 40-60 mg PO OR Hydrocortisone 100-200 mg IV<br>
    ‚Ä¢ Consider magnesium sulfate 2 g IV if poor response<br>
    <br>
    <strong>üî¥ LIFE-THREATENING ASTHMA (PEF <40%, silent chest, exhaustion):</strong><br>
    ‚Ä¢ Continuous salbutamol neb (10-15 mg/hr)<br>
    ‚Ä¢ Add Ipratropium 0.5 mg every 4-6 hours<br>
    ‚Ä¢ Magnesium sulfate 2 g IV over 20 minutes<br>
    ‚Ä¢ Consider IV salbutamol (ICU setting only)<br>
    ‚Ä¢ Prepare for intubation: Ketamine induction preferred<br>
    ‚Ä¢ ICU referral
</div>

<h3>Anaphylaxis Drug Dosing Quick Guide</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th>Drug</th>
            <th>Adult Dose</th>
            <th>Pediatric Dose</th>
            <th>Route</th>
            <th>Timing</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Adrenaline</strong></td>
            <td>0.3-0.5 mg</td>
            <td>0.01 mg/kg (max 0.3-0.5 mg)</td>
            <td>IM (thigh)</td>
            <td>Immediately, repeat q5-10min</td>
        </tr>
        <tr>
            <td><strong>Chlorphenamine</strong></td>
            <td>10 mg</td>
            <td>0.2 mg/kg (max 10 mg)</td>
            <td>IV/IM</td>
            <td>After adrenaline</td>
        </tr>
        <tr>
            <td><strong>Hydrocortisone</strong></td>
            <td>200 mg</td>
            <td>2-4 mg/kg (max 100 mg)</td>
            <td>IV/IM</td>
            <td>After adrenaline</td>
        </tr>
        <tr>
            <td><strong>Salbutamol neb</strong></td>
            <td>5 mg</td>
            <td>2.5 mg (<12y), 5 mg (>12y)</td>
            <td>Nebulized</td>
            <td>If bronchospasm</td>
        </tr>
        <tr>
            <td><strong>Fluids</strong></td>
            <td>500-1000 mL bolus</td>
            <td>20 mL/kg bolus</td>
            <td>IV</td>
            <td>If hypotensive</td>
        </tr>
    </tbody>
</table>

<h3>Monitoring Parameters for Respiratory Drugs</h3>
<ul>
    <li><strong>Continuous:</strong> SpO‚ÇÇ, ECG, respiratory rate</li>
    <li><strong>Every 15-30 minutes during treatment:</strong> Peak flow, work of breathing, auscultation</li>
    <li><strong>Hourly:</strong> Heart rate, blood pressure</li>
    <li><strong>Specific drug monitoring:</strong>
        <ul class="sub-list">
            <li><strong>Beta-agonists:</strong> Potassium (check q4-6h), glucose in diabetics</li>
            <li><strong>Aminophylline:</strong> Levels at 12-24h, ECG continuously</li>
            <li><strong>Magnesium:</strong> Reflexes during infusion, Mg level if renal impairment</li>
            <li><strong>Steroids:</strong> Glucose (especially in diabetics)</li>
        </ul>
    </li>
    <li><strong>ABG indications:</strong> Life-threatening features, deteriorating despite treatment, considering NIV/intubation</li>
</ul>

<div class="study-format">
    <h2><span class="emoji">üß†</span> DRUG TEMPLATE SUMMARY FOR MODULE 3</h2>
    <p><strong>All drugs in this module follow the same 11-point format:</strong></p>
    <ol>
        <li><strong>Drug class</strong> - Pharmacological category</li>
        <li><strong>Mechanism of action</strong> - How it works physiologically</li>
        <li><strong>Indications</strong> - When to use it (specific to respiratory/allergy)</li>
        <li><strong>Contraindications</strong> - Absolute and relative contraindications</li>
        <li><strong>Adult dose</strong> - Exact dosing (emergency situations)</li>
        <li><strong>Pediatric dose</strong> - Weight-based calculations</li>
        <li><strong>Route & preparation</strong> - How to prepare and administer</li>
        <li><strong>Side effects</strong> - Common, expected effects</li>
        <li><strong>Adverse effects / ADR</strong> - Serious, harmful reactions</li>
        <li><strong>Drug interactions</strong> - Important combinations to avoid/watch</li>
        <li><strong>Emergency pearls</strong> - Clinical tips, exam favorites, practical points</li>
    </ol>
</div>

<div class="footer-note">
    <strong>¬© Emergency Medicine Education Team | Confidential Educational Material</strong><br>
    This document is for educational purposes only. Always follow local protocols and guidelines.<br>
    Medications and doses may vary by institution. Verify all information before clinical application.<br>
    Version 1.0 | Last updated: [Current Date] | Module 3 of 10
</div>
</body> </html>